Multichannel Delivery System Optimal for Genetic Counseling in Ovarian Cancer
An interview study was conducted to determine preferences regarding information related to genetic counseling and testing among patients with ovarian cancer.
An interview study was conducted to determine preferences regarding information related to genetic counseling and testing among patients with ovarian cancer.
Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
The median progression-free survival was significantly longer with trametinib, compared with 1 of 5 standard care treatment options.
Researchers reviewed 92 trials and found that a majority placed restrictions on the control treatments physicians could choose.
The median overall survival was similar between the treatment arms.
Black race was significantly associated with not receiving a recommendation for chemotherapy.
Patients with a positive AGO score had better survival outcomes with surgery plus chemotherapy, compared with chemotherapy alone.
Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions.
The median PFS was 56.0 months with olaparib and 13.8 months with placebo.